GO
Loading...

Pharmaceuticals

More

  • Report: Prescription drug spending climbs in 2013 Tuesday, 15 Apr 2014 | 12:09 PM ET

    Total U.S. prescription drug spending climbed more than 3 percent last year, propelled in part by fewer patent expirations that would have allowed for cheaper generic alternatives, according to the data firm IMS Health. IMS Health also noted that 36 new treatments entered the market last year, including 10 for cancer.

  • April 15- Johnson& Johnson reported quarterly earnings well above expectations, as strong sales of new drugs offset weak demand for consumer products and medical devices, and the company slightly raised its full-year profit view. J&J on Tuesday said it earned $4.73 billion, or $1.64 per share, in the first quarter.

  • J&J beats forecasts, helped by new medicines Tuesday, 15 Apr 2014 | 10:06 AM ET

    Johnson & Johnson turned in a solid first quarter Tuesday, topping analysts' profit and revenue estimates and increasing its 2014 earnings forecast by 5 cents a share.

  • Americans start spending on health care again Tuesday, 15 Apr 2014 | 7:06 AM ET

    Americans used more health services and spent more on prescription drugs in 2013, reversing a recent trend.

  • ZURICH, April 15- A strong uptake of new cancer medicines helped Roche to limit a decline in first-quarter sales and the Swiss company confirmed a forecast for higher earnings this year.

  • *Q1 sales 11.496 bln Swiss francs vs 11.887 bln forecast. ZURICH, April 15- Adverse currency moves weighed on first-quarter sales at Roche Holding AG, which fell 1 percent, despite a healthy uptake of its new cancer medicines.

  • WASHINGTON, April 14- Generic drug manufacturers on Monday asked the U.S. Supreme Court to allow a lower court ruling favoring them to take effect while the high court considers an appeal in a patent fight over Teva Pharmaceutical Industries Ltd's top-selling multiple sclerosis drug, Copaxone.

  • Biotechs in the green after last week's carnage Monday, 14 Apr 2014 | 2:58 PM ET

    Shares of Biogen Idec, Celgene, Gilead Sciences, and Lexicon Pharmaceuticals recovered from last week's selloff.

  • Report: Glaxo bribed doctors in Poland Monday, 14 Apr 2014 | 9:00 AM ET

    LONDON— The BBC reports that pharmaceutical company GlaxoSmithKline is accused of bribing doctors to prescribe medicines in Poland. The British drug company faces corruption probes in China and Iraq.

  • *Allegations follow corruption accusations in China, Iraq. LONDON/ WARSAW, April 14- GlaxoSmithKline is facing a criminal investigation in Poland for allegedly bribing doctors to promote its lung drug Seretide, adding to problems for a company already accused of corruption in China and Iraq.

  • April 10- Rite Aid Corp, the third-largest U.S. drugstore operator, forecast fiscal 2015 sales above analysts' estimates as it benefits from the launch of new generic drugs and enrolls more customers in its loyalty programs.

  • WASHINGTON, April 10- The leading U.S. pharmaceutical industry trade group on Thursday defended the cost of Gilead Sciences Inc's new hepatitis C drug, Sovaldi, saying such treatments offer a priceless breakthrough for patients with the liver-destroying virus.

  • *France first EU country to allow biosimilar substitution. PARIS, April 10- France is going out on a limb with a plan to push the use of cheap copies of biotech drugs, triggering alarm among companies in Europe's second-biggest pharmaceutical market behind Germany.

  • Pfizer CEO worries about ACA coverage     Thursday, 10 Apr 2014 | 11:43 AM ET

    Ian Read, Pfizer CEO, discusses the pricing and affordability of drugs in the U.S. Read also weighs in on insurance coverage under the Affordable Care Act.

  • MUMBAI, April 10- India's Natco Pharma Ltd has formally asked the Indian patent office to deny U.S. drugmaker Gilead Sciences Inc's new hepatitis C drug Sovaldi a patent in India, a source with direct knowledge of the matter said.

  • CNBC's Jim Cramer speaks with Robert Hugin, Celgene chairman & CEO, about America's need to build a stronger and more sustainable ecosystem of innovation to continue as the world leader in biomedical innovation.

  • Alkermes is a true drug innovator: CEO     Thursday, 10 Apr 2014 | 8:21 AM ET

    Richard Pops, chairman & CEO of Alkermes, discusses Alkermes' new injectable drug for the treatment of schizophrenia. We have more psychiatry products in our pipeline, reveals Pops.

  • *France first EU country to allow biosimilar substitution. PARIS, April 10- France is going out on a limb with a plan to push the use of cheap copies of biotech drugs, triggering alarm among companies in Europe's second-biggest pharmaceutical market behind Germany.

  • April 10- A combination of two anti-viral drugs developed by Bristol-Myers Squibb Co cured 90 percent of previously untreated hepatitis C patients and 82 percent of those who failed to respond to prior therapy, according to results from a late stage study presented on Thursday.

  • Eli Lilly CEO: We keep investing in R&D     Thursday, 10 Apr 2014 | 6:51 AM ET

    John Lechleiter, Chairman, President & CEO of Eli Lilly, discusses the company's growth plans as products come off patent and consumers move to generic drugs.

Most Popular Video

Wednesday, 16 Apr 2014 | 9:37 AM ET

CNBC's Bob Pisani looks at what's likely to move in early morning trading, including the public debut of Moelis & Company, and a look at bank earnings and market leaders.

Wednesday, 16 Apr 2014 | 7:50 AM ET

John Calipari, University of Kentucky basketball coach, discusses building "servant leadership" in his team, and the big business of college basketball.

Wednesday, 16 Apr 2014 | 9:04 AM ET

The "Squawk on the Street" news team break down Bank of America's Q1 earnings loss thanks largely to legal expenses related to the financial crisis.